Espoo, Finland

Aino K Pippuri


Average Co-Inventor Count = 6.4

ph-index = 7

Forward Citations = 281(Granted Patents)


Company Filing History:


Years Active: 1981-2005

Loading Chart...
20 patents (USPTO):Explore Patents

Title: Aino K Pippuri: Innovator in Anti-inflammatory and Cardiovascular Therapeutics

Introduction

Aino K Pippuri, based in Espoo, Finland, is a prolific inventor with an impressive portfolio of 20 patents. His groundbreaking work primarily focuses on anti-inflammatory agents and treatments for congestive heart failure, marking significant advancements in the field of medical therapeutics.

Latest Patents

Among his latest innovations, Pippuri has developed anti-inflammatory agents that utilize mitochondrial K-channel openers. These compounds, particularly those of general formula (I), are designed for the treatment or prevention of inflammation by inducing apoptosis in inflammatory cells. Furthermore, he has introduced pyridazinyl phenyl hydrazones that show promise against congestive heart failure, highlighting his dedication to improving cardiovascular health.

Career Highlights

Pippuri has made significant contributions while employed at Orion-yhtyma Oy and Orion Corporation. His work in these esteemed organizations has not only fostered innovation but has also enhanced the potential for commercial applications of his inventions within the pharmaceutical industry.

Collaborations

Throughout his career, Aino K Pippuri has collaborated with notable colleagues such as Erkki J Honkanen and Erkki A Nissinen. Their combined expertise has undoubtedly propelled the advancement of their research and development efforts, further establishing Pippuri's reputation as a leading inventor in his field.

Conclusion

Aino K Pippuri's contributions to the medical field through his innovative patents underscore his role as a significant figure in the realm of pharmaceuticals. His work continues to inspire new treatments and therapies, particularly in the areas of inflammation and cardiovascular diseases, solidifying his legacy in medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…